<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113681</url>
  </required_header>
  <id_info>
    <org_study_id>Geniculate embolization.</org_study_id>
    <nct_id>NCT04113681</nct_id>
  </id_info>
  <brief_title>Pilot Study: Geniculate Artery Embolization in Knee Osteoarthrosis.</brief_title>
  <official_title>Pilot Study: Geniculate Artery Embolization in Knee Osteoarthrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Geniculate Artery Embolization (GAE) has recently been described and studied as a palliative
      treatment for osteoarthrosis-related knee pain in patients un-eligible for surgical
      intervention. This treatment is based on the hypothesis that hypervascularization and
      associated increased nerve proliferation are possible sources of chronic pain following the
      morphological changes of osteoarthrosis. A large animal model has shown digital subtraction
      arteriography to be well correlated to both the histological findings of synovial
      inflammation and synovial contrast enhancement on magnetic resonance imaging. This
      embolization technique has also been applied to other regions of the musculoskeletal system
      including the elbow and the shoulder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective Confirm the efficacy and the effectiveness of geniculate artery
      embolization for pain control in knee osteoarthrosis.

      Secondary Objective Evaluate the effectiveness of geniculate artery embolization for pain
      control in specific population: young patients between 18 and 50 years old with advanced
      osteoarthritis (KL grade 3 or 4) for whom an orthopedic surgeon has deemed a total knee
      arthroplasty is not an appropriate therapy, and whom have failed conservative management for
      at least 6 months.

      Investigators propose a prospective pilot study on 40 patients with osteoarthrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will be stratified into two groups:
Group 1: Patients between 18-50 years old with KL grade 3-4
Group 2: Patients age 50 years old and over with KL grade 1-4</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control VAS</measure>
    <time_frame>12 months</time_frame>
    <description>The pain intensity is assessed using VAS (horizontal line 100 mm in length). Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing &quot;No Pain&quot; and 100 mm representing &quot;Worst Possible Pain&quot;.
Expected mean VAS pre treatment: 7
Expected mean VAS at 1, 3, 6 and 12 months: 3-4 (50% reduction)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>12 months</time_frame>
    <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Subcategories of pain (5 items), stiffness (2 items), and physical function (17 items). Individuals select the level of difficulty they have performing various tasks using a 5 points Likert scale (0=None, 1=Slightly, 3=Very, 4=Extremely). Results are scored with a total maximum score of 96. A higher score indicates more difficulty in each of the categories.
Expected mean WOMAC score pre treatment: 50
Expected mean WOMAC score at 1, 3, 6 and 12 months: 25 (50% reduction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological examinations</measure>
    <time_frame>12 months</time_frame>
    <description>Knee x-ray examinations
Knee MRI (if a complication is suspected clinically)
Sustained response expected to be less likely with increased KL grade</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Geniculate Artery Embolization Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Geniculate Artery Embolization</intervention_name>
    <description>Conscious sedation : midazolam and fentanyl
Local anesthesia : Lidocaine 2% subcutaneous
Retrograde or anterograde common femoral artery access - 4Fr introducer
Sub-therapeutic anticoagulation (heparin 2000 IU IA)
Lower extremity arteriography
Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee
If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.
Angiographic end-points: embolization of abnormal blush while preserving the parent vessel
Arteriotomy closure (manual compression or closure device)</description>
    <arm_group_label>Geniculate Artery Embolization Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Moderate to severe knee pain (visual analog scale (VAS) &gt; 70 mm)

          -  Pain refractory to at least 6 months of conservative therapies (anti-inflammatory
             drugs, or physical therapy, or muscle strengthening, or intra-articular injections)

          -  Localized pain on physical examination

          -  Kellgren-Lawrence (KL) Score on knee X-Ray

          -  Patients 50 years old and over : grade 1, 2, 3 or 4

          -  18-50 years old: KL grade 3 or 4

        Exclusion Criteria:

          -  Current local infection

          -  Life expectancy less than 6 months

          -  Known advanced atherosclerosis

          -  Rheumatoid or infectious arthritis

          -  Prior knee surgery

          -  Uncorrectable coagulopathy including international normalized ratio (INR) &gt; 1.5 or
             platelets &lt; 50,000

          -  Iodine allergy

          -  Renal dysfunction as defined by GFR &lt; 60ml/min obtained within the past 30 days.

          -  Diabetic patient

          -  Previous embolization of the geniculate arteries during the last year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Cengarle-Samak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS de l'Est-de-l'Ile-de-Montreal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Cengarle-Samak, MD</last_name>
    <phone>514-252-3400</phone>
    <email>alexandre.cengarle-samak@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascal Andre Vendittoli, MD</last_name>
    <phone>514-252-3400</phone>
    <email>pa.vendittoli@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Île-de-Montréal, Installation Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Cengarle-Samak, MD</last_name>
      <phone>514-252-3400</phone>
      <email>alexandre.cengarle-samak@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Pascal Andre Vendittoli, MD</last_name>
      <phone>514-252-3400</phone>
      <email>pa.vendittoli@me.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre Cengarle-Samak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Andre Vendittoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Caty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel-Pierre Dufresne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Dubé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>van Baardewijk LJ, Hoogeveen YL, van der Geest ICM, Schultze Kool LJ. Embolization of the Geniculate Arteries Is an Effective Treatment of Recurrent Hemarthrosis Following Total Knee Arthroplasty That Can Be Safely Repeated. J Arthroplasty. 2018 Apr;33(4):1177-1180.e1. doi: 10.1016/j.arth.2017.11.002. Epub 2017 Nov 24.</citation>
    <PMID>29224993</PMID>
  </reference>
  <reference>
    <citation>Bagla S, Rholl KS, van Breda A, Sterling KM, van Breda A. Geniculate artery embolization in the management of spontaneous recurrent hemarthrosis of the knee: case series. J Vasc Interv Radiol. 2013 Mar;24(3):439-42. doi: 10.1016/j.jvir.2012.11.011.</citation>
    <PMID>23433418</PMID>
  </reference>
  <reference>
    <citation>Okuno Y, Korchi AM, Shinjo T, Kato S, Kaneko T. Midterm Clinical Outcomes and MR Imaging Changes after Transcatheter Arterial Embolization as a Treatment for Mild to Moderate Radiographic Knee Osteoarthritis Resistant to Conservative Treatment. J Vasc Interv Radiol. 2017 Jul;28(7):995-1002. doi: 10.1016/j.jvir.2017.02.033. Epub 2017 Mar 30.</citation>
    <PMID>28365171</PMID>
  </reference>
  <reference>
    <citation>Okuno Y, Korchi AM, Shinjo T, Kato S. Transcatheter arterial embolization as a treatment for medial knee pain in patients with mild to moderate osteoarthritis. Cardiovasc Intervent Radiol. 2015 Apr;38(2):336-43. doi: 10.1007/s00270-014-0944-8. Epub 2014 Jul 4.</citation>
    <PMID>24993956</PMID>
  </reference>
  <reference>
    <citation>Iwamoto W, Okuno Y, Matsumura N, Kaneko T, Ikegami H. Transcatheter arterial embolization of abnormal vessels as a treatment for lateral epicondylitis refractory to conservative treatment: a pilot study with a 2-year follow-up. J Shoulder Elbow Surg. 2017 Aug;26(8):1335-1341. doi: 10.1016/j.jse.2017.03.026.</citation>
    <PMID>28734535</PMID>
  </reference>
  <reference>
    <citation>Okuno Y, Iwamoto W, Matsumura N, Oguro S, Yasumoto T, Kaneko T, Ikegami H. Clinical Outcomes of Transcatheter Arterial Embolization for Adhesive Capsulitis Resistant to Conservative Treatment. J Vasc Interv Radiol. 2017 Feb;28(2):161-167.e1. doi: 10.1016/j.jvir.2016.09.028. Epub 2016 Dec 19.</citation>
    <PMID>28007330</PMID>
  </reference>
  <reference>
    <citation>Okuno Y, Oguro S, Iwamoto W, Miyamoto T, Ikegami H, Matsumura N. Short-term results of transcatheter arterial embolization for abnormal neovessels in patients with adhesive capsulitis: a pilot study. J Shoulder Elbow Surg. 2014 Sep;23(9):e199-206. doi: 10.1016/j.jse.2013.12.014. Epub 2014 Mar 4.</citation>
    <PMID>24618195</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Alexandre Cengarle-Samak</investigator_full_name>
    <investigator_title>Interventional radiologist</investigator_title>
  </responsible_party>
  <keyword>Embolization, Osteoarthritis, Knee, Geniculate Artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

